Key result
Amlodipine and carvedilol significantly reduced elevated serum biomarkers such as CK-MB and LDH, demonstrating cardioprotective effects against cyclophosphamide-induced cardiotoxicity in rats.
Why the study?
Cyclophosphamide causes cardiotoxicity, leading to the evaluation of whether amlodipine and carvedilol exert cardioprotective effects against it.
Does amlodipine or carvedilol prevent cyclophosphamide-induced cardiotoxicity in albino Wistar rats?
Does amlodipine or carvedilol prevent cyclophosphamide-induced cardiotoxicity in albino Wistar rats?
Absolute Event Rate: 36.4% vs 101.5%
p-value: p=<0.001
Amlodipine and carvedilol demonstrated cardioprotective effects against cyclophosphamide-induced cardiotoxicity in a rat model by improving oxidative stress markers and ECG parameters.
May support further rat-model investigation of amlodipine and carvedilol; leaves open clinical translation for cyclophosphamide cardiotoxicity.
Cardiotoxicity is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. The mechanism of anthracycline induced cardiotoxicity seems to involve the formation of free radicals leading to oxidative stress. This may cause apoptosis of cardiac cells or immunologic reactions.CYP has been recorded to be carditoxic. Amlodipine and carvedilol has been exploited to test its cardioprotective activityvon CYP induced cardiotoxicity. Objective: the aim of this study was assessment of cardioprotective effect of Amlodipine and carvedilol on CYP induced cardiotoxicity in albino wistar rats by measuring the enzymatic, non-enzymatic antioxidant levels, serum enzyme levels and study of ECG alteration. Materials Methods: Albino wistar rats were allotted in to 4 groups (6 rats/group), normal control: (i.p. injection with normal saline), CYP group (200 mg/kg ip), Alodipine and CYP group (Amlo-10 mg/kg oral & CYP- 200 mg/kg ip), carvediol and CYP group (Carve-3mg/kg oral & CYP- 200 mg/kg ip) for 10 days of duration and ECG was measured using power lab software. Results: cardioprotects of amlodipine and carvediol significantly reduced the elevated levels of serum biomarkers like CK, CK-MB, LDH, calcium when compare to CYP induced cardiotoxicity. Amlodipine and carvediol has shown significant increase in the levels of tissue biomarkers such as SOD, GSH, catalase when compare to CYP induced cardiotoxicity. In Histopathological studies, the group treated with amlodipine + CYP and carvediol + CYP has shown intact arrangement of cardiac muscle fibres, intact integrity of myocardial cell membrane, myofibrillar structure with striations and continuity with adjacent myofibrils. Considering improvement in the serum biomarker levels and tissue biomarker levels amlodipine and carvediol showed cardioprotective activity. Finally it concluded that amlodipine and carvediol has cardio protective effect on cyclophosphamide induced rats.
No takes yet. Share an insight, caveat, or question.
Akshata et al. (2022) studied Cyclophosphamide-induced cardiotoxicity (n=24). Amlodipine and Carvedilol vs. Cyclophosphamide 200 mg/kg ip (toxic control) was evaluated on Serum CK-MB level (IU/L) (p=<0.001). Amlodipine and carvedilol significantly reduced elevated serum biomarkers such as CK-MB and LDH, demonstrating cardioprotective effects against cyclophosphamide-induced cardiotoxicity in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: